April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Ranibizumab Dose Comparison for the Treatment of Diabetic Macular Edema
Author Affiliations & Notes
  • Philip J. Ferrone
    Ophthalmology, North Shore University Hospital; Columbia Univ., Great Neck, New York
  • Jon Jonisch
    Ophthalmology, North Shore University Hospital, Great Neck, New York
  • Footnotes
    Commercial Relationships  Philip J. Ferrone, Genentech (F, C, R); Jon Jonisch, None
  • Footnotes
    Support  Unrestricted Investigator Sponsored Trial Supported by Genentech
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5333. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Philip J. Ferrone, Jon Jonisch; Ranibizumab Dose Comparison for the Treatment of Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5333.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare ranibizumab dose response in the treatment of clinically significant diabetic macular edema.

Methods: : Investigator sponsored, prospective, randomized clinical trial. Eyes with clinically significant macular secondary to diabetic retinopathy were randomized to one of two groups, 0.5mg or 1.0mg ranibizumab at baseline. During the first year, three monthly injections were given followed by as-needed injections on alternate months. Starting at Month 12, patients were followed monthly and could receive as-needed treatments at these visits. An amendment allowed treatment with 2.0mg ranibizumab in patients who had completed at least 12 months of follow-up.

Results: : : A 24-month interim analysis was performed. Both groups had similar baseline characteristics. At Month 24, significant visual acuity gains from baseline were observed in both 0.5mg and 1.0 mg groups. There was a significant mean decrease in central foveal thickness in both the 0.5mg and 1.0mg groups. In the 0.5mg group, a smaller proportion of patients gained 15 or more ETDRS letters compared to patients in the 1.0mg group. The average number of injections in the 0.5mg group was similar as compared to the 1.0mg group. Fifteen patients received 2.0mg ranibizumab starting at or after Month 24. In this subset, visual and anatomic outcomes were maintained through follow-up. When compared to the 6 months preceding the transition to the 2.0mg dose, the average time (days) between treatments increased in both groups (0.5mg vs 2.0mg: 49 vs 66; and, 1.0mg vs 2.0mg: 45 vs 56).

Conclusions: : Treatment of CSDME with 1.0 mg of ranibizumab resulted in a statistically significant improvement in visual acuity from baseline. There was a trend towards greater improvement in ETDRS visual acuity and improved resolution of macular edema with 1.0 mg ranibizumab versus 0.5 mg ranibizumab at 24 months. The number of injections did not differ significantly between the two groups.

Clinical Trial: : http://www.clinicaltrials.gov NCT00440609

Keywords: diabetic retinopathy • edema • diabetes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×